AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:

$$R_1$$
 R_2
 $X-Z$
 R_3
 R_3
 R_1
 R_2
 R_3

wherein

Z represents a carboxylic acid group (-COOH) or an ester thereof;

 R_1 and R_3 independently represent H; F; Cl; Br; -NO₂; -CN; C₁-C₆ alkyl optionally substituted by F or Cl; or C₁-C₆ alkoxy optionally substituted by F;

R₂ represents optionally substituted C₇ cycloalkyl, substituted C₃-C₇ cycloalkyl or optionally substituted phenyl;

Y represents -O-, -S-, N-oxide, or -N(R₅)- wherein R₅ represents H or C₁-C₆ alkyl; and

X represents a bond or a group selected from; a divalent C_1 - C_6 alkylene radical, NHC(O) C_{1-5} alkyl or NHC(O) CH_2 -O- CH_2 .

- 2. (Previously Presented) The compound of claim 1 wherein X is a bond or a $-CH_2$ -or $-CH_2CH_2$ radical.
 - 3. (Previously Presented) The compound of claim 1 wherein Z is -COOH.
- 4. (Previously Presented) The compound of claim 1 wherein R_1 is H, F, Cl, methyl, methoxy, or methylenedioxy.

- 5. (Previously Presented) The compound of claim 1 wherein R₂ is cyclopropyl, phenyl, or fluoro-, chloro-, methyl, methoxy-, nitro-, or amino- substituted phenyl.
- 6. (Previously Presented) The compound of claim 1 wherein R₃ is H, F, Cl, methyl, methoxy, or methylenedioxy.
- 7. (Previously Presented) The compound of claim 1 wherein Y is $-N(R_5)$ wherein R_5 represents H or methyl.
 - 8. (Canceled).
- 9. (Previously Presented) A medicament for the treatment of conditions which benefit from immunomodulation comprising an effective dose of the compound of claim 1.
- 10. (Previously Presented) A method of immunomodulation in mammals, including humans, comprising administering to a mammal in need of such treatment an immunomodulatory effective dose of the compound of claim 1.
- 11. (Previously Presented) A pharmaceutical or veterinary composition comprising the compound of claim 1 together with a pharmaceutically or veterinarily acceptable excipient or carrier.
 - 12. (Previously Presented) The compound of claim 2 wherein Z is -COOH.
- 13. (Previously Presented) The compound of claim 2 wherein R_1 is H, F, Cl, methyl, methoxy, or methylenedioxy.
- 14. (Previously Presented) The compound of claim 2 wherein R₂ is cyclopropyl, phenyl, or fluoro-, chloro-, methyl, methoxy-, nitro-, or amino- substituted phenyl.
- 15. (Previously Presented) The compound of claim 2 wherein R₃ is H, F, Cl, methyl, methoxy, or methylenedioxy.

- 16. (Previously Presented) The compound of claim 2 wherein Y is $-N(R_5)$ wherein R_5 represents H or methyl.
- 17. (Previously Presented) A method of immunomodulation in mammals, including humans, comprising administering to a mammal in need of such treatment an immunomodulatory effective dose of the compound of claim 2.
- 18. (Previously Presented) A method of immunomodulation in mammals, including humans, comprising administering to a mammal in need of such treatment an immunomodulatory effective dose of the compound of claim 3.
- 19. (Previously Presented) A pharmaceutical or veterinary composition comprising the compound of claim 2 together with a pharmaceutically or veterinarily acceptable excipient or carrier.
- 20. (Previously Presented) A pharmaceutical or veterinary composition comprising the compound of claim 3 together with a pharmaceutically or veterinarily acceptable excipient or carrier.
- 21. (Previously Presented) A pharmaceutical or veterinary composition comprising the compound of claim 4 together with a pharmaceutically or veterinarily acceptable excipient or carrier.